Skip to main
BCTX

BCTX Stock Forecast & Price Target

BCTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BriaCell Therapeutics has recently received a non-dilutive $2 million grant from the US National Cancer Institute to advance its Bria-PROS+ program, which is crucial for its clinical development in metastatic prostate cancer. This funding will facilitate the completion of clinical supply manufacturing and support the ongoing Phase 1/2a trials for Bria-OTS, enhancing the company's portfolio of immunotherapy solutions. The successful advancement of these programs indicates BriaCell's strong position and potential for growth in the biotechnology sector focused on innovative cancer treatments.

Bears say

BriaCell Therapeutics faces several significant risks that contribute to a negative outlook for the company's stock, including potential safety signals emerging from clinical programs and lower-than-expected efficacy in ongoing studies. The company anticipates needing approximately $120 million in additional financing through 2037, raising concerns about its financial stability and ability to fund operations. Furthermore, the competitive landscape for cancer treatments poses additional pressure, with existing and developing alternatives, along with possible regulatory challenges impacting the commercialization of BriaCell's immunotherapies.

BCTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BriaCell Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BriaCell Therapeutics (BCTX) Forecast

Analysts have given BCTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, BCTX has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BriaCell Therapeutics (BCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.